Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy
Glioblastoma, the most common primary brain cancer in adults, is characterized by a poor prognosis and resistance to standard treatments. The advent of immunotherapy has revolutionized the treatment of several cancers in recent years but has failed to demonstrate benefit in patients with glioblastom...
Main Authors: | Catherine Yu, Kristin Hsieh, Daniel R. Cherry, Anthony D. Nehlsen, Lucas Resende Salgado, Stanislav Lazarev, Kunal K. Sindhu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/12/12/1528 |
Similar Items
-
Gene Targets of CAR-T Cell Therapy for Glioblastoma
by: Chaoqun Wang, et al.
Published: (2023-04-01) -
Advances in Immunotherapy for Adult Glioblastoma
by: Chirayu R. Chokshi, et al.
Published: (2021-07-01) -
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
by: Stephanie Sanders, et al.
Published: (2020-04-01) -
CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement
by: Ayush Pant, et al.
Published: (2023-02-01) -
Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
by: Mark Dapash, et al.
Published: (2021-09-01)